Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres-Reference-Cited by-同舟云学术

Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres

Published:2024-08-21 Issue:1 Volume:56 Page:
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Liu Jing¹^ORCID,Du Qianyu²,Shao Yu³,Xu Han⁴,Liu Xiuli⁵,Zhang Wenting¹,Wang Mingxi¹,Zhou Zhengguang¹,Kan Qingsheng²,Yang Yan¹^ORCID

Affiliation:

1. Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

2. Department of Oncology, Suzhou Hospital Affiliated to Anhui Medical University, Suzhou, China

3. National Drug Clinical Trial Centre, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

4. Department of Medical Oncology, The Third People’s Hospital of Bengbu, Bengbu, China

5. Department of Oncology, The Fifth People’s Hospital of Fuyang, Fuyang, China

Funder

the Natural Science Research Major Project of Universities of Anhui Province

the Excellent Youth Talents Support Program in Higher Education Institutions of Anhui Province

the 512 Talent Cultivation Plan of Bengbu Medical College

the Science Fund for Distinguished Young Scholars of the First Affiliated Hospital of Bengbu Medical College

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2024.2393291

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

3. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

4. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

5. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma